ARTICLE SUMMARY:
What the US midterm election's seismic congressional shift might mean for medtech legislation and oversight; Moving toward consensus on change control practices in the EU, AngioSafe's Khushbu Shah on building a postmarket strategy that satisfies both US and MDR requirements; US and UK regulators seek leeway for marketed AI-enabled devices to adapt; Mandatory bundled payments are coming to orthopedics; FDA panel approval for MCED screening test sparks controversy.